Possible mechanisms of action of (−)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders
- 1 October 1994
- journal article
- review article
- Published by Elsevier in Progress in Neurobiology
- Vol. 44 (2) , 141-161
- https://doi.org/10.1016/0301-0082(94)90036-1
Abstract
No abstract availableThis publication has 149 references indexed in Scilit:
- Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidasePublished by Elsevier ,2004
- Chronic treatment of (-)deprenyl prolongs the life span of male fischer 344 rats. Further evidenceLife Sciences, 1993
- L-Deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brainNeuroReport, 1993
- A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's diseaseAnnals of Neurology, 1993
- The effects of some neuroleptics and d-amphetamine on striatal 2-phenylethylamine in the mouseGeneral Pharmacology: The Vascular System, 1991
- (?)-Deprenyl can induce soluble superoxide dismutase in rat striataJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1991
- Deprenyl for the Treatment of Early Parkinson's DiseaseNew England Journal of Medicine, 1990
- L-deprenyl plus l-phenylalanine in the treatment of depressionJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1984
- Time course of nigrostriatal degeneration in parkinson's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1976
- The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenilJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1975